Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.

Tirzepatide may improve hair loss by reducing insulin resistance.

Two women had skin reactions from a hair loss treatment and got better after stopping use.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

New isatin-gallate hybrids show promise as antioxidants, cancer treatments, and coronavirus inhibitors.

Both oral contraceptives reduced hirsutism in PCOS patients, but adding metformin showed no extra benefit.

CTP-543 is generally safe for treating alopecia areata.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Pexidartinib often causes liver issues and fatigue, especially in women.